InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting on its end-of-phase-2 meeting with the U.S. Food and Drug Administration (“FDA”). The meeting was regarding CYB003, the company’s deuterated psilocybin analog for the adjunctive treatment of major depressive disorder (“MDD”), and Cybin’s phase 2 study in MDD,…